Kenneth Carl Anderson

Synthetic lethality of p97 inhibition and PSMC2-overexpressionovercomes bortezomib resistance in multiple myeloma

This study identifies PSMC2 overexpression as a driver of bortezomib resistance in multiple myeloma and shows that combining p97 inhibition with bortezomib overcomes this resistance.

Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs

This study uses dry mass and volume measurements to assess early response of multiple myeloma cells to proteotoxic and genotoxic treatments, finding dry mass increases correlate with bortezomib sensitivity.

Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study

The paper identifies genomic subtypes of multiple myeloma using the MMRF CoMMpass study and finds that 25.5% of patients transition to a high-risk expression subtype at progression, which expresses immunotherapy targets.

Revealing the impact of recurrent and rare structural variants in multiple myeloma

This study identifies 100 SV hotspots and 31 new candidate driver genes in multiple myeloma, revealing that 63% of SVs remain unexplained and are associated with outlier gene expression.